Please ensure Javascript is enabled for purposes of website accessibility

Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study

By Todd Campbell - Feb 11, 2020 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cabozantinib may help delay the need for chemotherapy in advanced patients.

Exelixis (EXEL 1.15%) already markets cabozantinib as a treatment for kidney cancer and liver cancer; its latest results suggest it may secure approval for its use in prostate cancer someday, too.

Interim results from a phase 1b trial showed that 32% of 44 metastatic castration-resistant prostate cancer (CRPC) patients responded to a combination of cabozantinib, which is marketed under the brand name Cabometyx, and Roche's (RHHBY -0.62%) Tecentriq, a PD-1 inhibitor.

Hands arrange pieces of construction paper into an upwardly ascending arrow.

IMAGE SOURCE: GETTY IMAGES.

The responses include 12 partial responses and two complete responses. Including patients with stable disease, the disease control rate was 80%. Safety doesn't appear to be concerning either, given that just 7% of patients discontinued the study because of adverse events.

The findings suggest Cabometyx may help delay the need for chemotherapy in advanced patients who have few other treatment options. According to the American Cancer Society, nearly 200,000 men are diagnosed with prostate cancer annually, and 33,000 die from it every year. In 2020, approximately 43,000 prostate cancer patients will progress to metastatic CRPC, a diagnosis with a median survival time of less than two years.

Exelixis is expanding the number of patients enrolled in its metastatic CRPC trial; if data from the new patients is similarly positive, then management hopes to file for accelerated FDA approval of Cabometyx in this indication as soon as 2021. Net sales of Cabometyx totaled $800 million in 2019; Exelixis estimates that approvals in metastatic CRPC could add $600 million annually to net product sales by 2025, making this biotech stock worth watching.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$18.40 (1.15%) $0.21
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$43.06 (-0.62%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.